Home›Sensitive Cyp3a Substrates›Sensitive Cyp3a Substrates + Olutasidenib

Does Sensitive Cyp3a Substrates Interact with Olutasidenib?

Sensitive Cyp3a Substrates and Olutasidenib have a major drug interaction according to U.S. FDA drug labeling data. Olutasidenib induces CYP3A and may decrease plasma concentrations of sensitive CYP3A substrates, reducing their efficacy. Avoid concomitant use or monitor for loss of therapeutic effect. The mechanism involves olutasidenib induces cyp3a, decreasing substrate plasma concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Sensitive Cyp3a Substrates and Olutasidenib occurs because olutasidenib induces cyp3a, decreasing substrate plasma concentrations. Clinically, this means olutasidenib induces cyp3a and may decrease plasma concentrations of sensitive cyp3a substrates, reducing their efficacy. avoid concomitant use or monitor for loss of therapeutic effect. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Sensitive Cyp3a Substrates and your doctor is considering prescribing Olutasidenib (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Sensitive Cyp3a Substrates+💊 Olutasidenib(Rezlidhia)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
—
Source
NLP:olutasidenib

What this means in plain English

Olutasidenib induces CYP3A and may decrease plasma concentrations of sensitive CYP3A substrates, reducing their efficacy. Avoid concomitant use or monitor for loss of therapeutic effect.

What the FDA label says

"Olutasidenib induces CYP3A, decreasing substrate plasma concentrations"

📖 Source: NLP:olutasidenib

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Sensitive Cyp3a Substrates and Olutasidenib against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.